Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena

Journal of Pharmaceutical Sciences

Volumn 87, Issue 12, 1998, Pages 1577-1584

  Sharma, Amarnath ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE DERIVATIVE; CATECHOLAMINE; DRUG; NEUROHORMONE; PROLACTIN; REMOXIPRIDE; TYRAMINE;

ARTICLE; COMPUTER SIMULATION; DESENSITIZATION; DOSE RESPONSE; DRUG DOSE; DRUG EXPOSURE; DRUG RESPONSE; DRUG TOLERANCE; MODEL; PRECURSOR; REBOUND;

EID: 0031742890     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js980171q     Document Type: Article

References (18)

1. Sibley, D. R.; Lefkowitz, R. J. Molecular mechanisms of receptor desensitization using the /?-adrenergic receptorcoupled adenylate cyclase system as a model. Nature 1985, 317, 124-129.
2. Lima, J. J.; Krukemyer, J. J.; Boudoulas, H. Drug- or hormone-induced adaptation: model of adrenergic hypersensitivity, J. Pharmacokin. Biopharm. 1989, 77, 347-364.
3. Ariens, E. J.; Simonis, A. M. In Ariens, E. J., Ed.; Molecular pharmacology: The mode of action of biologically active compounds', Academic Press: New York and London, 1964; Vol. I, pp 105-118.
4. Guyton, A. C. Blood pressure control-special role of the kidneys and body fluids. Science 1991, 252, 1813-1816.
5. Movin-Osswald, G.; Hammarlund-Udenaes, M. Prolactin release after rempxipride by an integrated pharmacokineticpharmacodynamic model with intra- and inter-individual aspects. J. Pharmacol. Exp. Ther. 1995, 274, 921-927.
6. Houston, M. C.; Hodge, R. Beta-adrenergic blocker withdrawal syndromes in hypertension and other cardiovascular diseases. Am. Heart J. 1988, 776, 515-523.
7. Ekblad, E. B. M.; Licko, V. A model eliciting transient responses. Am. J. Physiol. 1984, 246, R114-R121.
8. Dayneka, N. L.; Garg, V.; Jusko, W. J. Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 1993, 21, 457-478.
9. D'Argenio, D. Z.; Schumitzky, A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comp. Programs Biomed. 1979, 9, 115-134.
10. Sharma, A.; Jusko, W. J. Characterization of four basic models of indirect pharmacodynamic responses. J. Pharmacokin. Biopharm. 1996, 24, 611-635.
11. Krzyzanski, W.; Jusko, W. J. Integrated functions for four basic models of indirect pharmacodynamic response. J. Pharm. Sci. 1998, 87, 67-72.
12. Sun, Y.-N.; Jusko, W. J. Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. J. Pharm. Sci. 1998, 87, 732-737.
13. Aarons, R. D.; Nies, A. S.; Gal, J.; Hegstrand, L. R.; Molinoff, P. B. Elevation of /î-adrenergic receptor density in human lymphocytes after propranolol administration. J. Clin. Invest. 1980, 65, 949-957.
14. Packer, M.; Lee, W. H.; Kessler, P. D.; Gottlieb, S. S.; Medina, N.; Yushak, M. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. New Engl. J. Med. 1987,317, 299-304.
15. Sun, Y.-N.; DuBois, D. C.; Almon, R. R.; Jusko, W. J. Fourthgeneration model for corticosteroid pharmacodynamics: A model for methylprednisolone effects on receptor/gene-mediated glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver. J. Pharmacokin. Biopharm. 1998, in press.
16. Wakelkamp, M.; Alvan, G.; Gabrielsson, J.; Paintaud, G. Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration. Clin. Pharmacol. Ther. 1996, 60, 75-88.
17. Bauer, J. A.; Fung, H. L. Pharmacodynamic models of nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Pharm. Res. 1994, 11, 816-823.
18. Mandema, J. W.; Wada, D. R. Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat. J. Pharmacol. Exp. Ther. 1995, 275, 1185-1194.